tiprankstipranks

Vanda Pharmaceuticals’ New Drug Application Accepted by FDA

Story Highlights
  • Vanda Pharmaceuticals’ tradipitant application for motion sickness was accepted by the FDA.
  • Vanda criticized the FDA for delaying the review, impacting innovation and public health.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA

Vanda ( (VNDA) ) has shared an update.

On March 14, 2025, Vanda Pharmaceuticals announced that the FDA has accepted its new drug application for tradipitant, aimed at treating motion sickness, with a decision expected by December 30, 2025. Despite successful trials showing significant efficacy in reducing motion-induced vomiting, Vanda criticized the FDA for delaying the review process, highlighting concerns about the agency’s impact on innovation and public health.

More about Vanda

Vanda Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative therapies to address unmet medical needs. The company primarily develops drugs for central nervous system disorders and other medical conditions.

YTD Price Performance: 3.32%

Average Trading Volume: 646,401

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $290.4M

For an in-depth examination of VNDA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App